Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
The DOI matches its Crossref record; 17 of the 18 references it cites were found in a registry or an index.
Abstract
Six healthy young male volunteers at a contract research organization were enrolled in the first phase 1 clinical trial of TGN1412, a novel superagonist anti-CD28 monoclonal antibody that directly stimulates T cells. Within 90 minutes after receiving a single intravenous dose of the drug, all six volunteers had a systemic inflammatory response characterized by a rapid induction of proinflammatory cytokines and accompanied by headache, myalgias, nausea, diarrhea, erythema, vasodilatation, and hypotension. Within 12 to 16 hours after infusion, they became critically ill, with pulmonary infiltrates and lung injury, renal failure, and disseminated intravascular coagulation. Severe and unexpected depletion of lymphocytes and monocytes occurred within 24 hours after infusion. All six patients were transferred to the care of the authors at an intensive care unit at a public hospital, where they received intensive cardiopulmonary support (including dialysis), high-dose methylprednisolone, and an anti-interleukin-2 receptor antagonist antibody. Prolonged cardiovascular shock and acute respiratory distress syndrome developed in two patients, who required intensive organ support for 8 and 16 days. Despite evidence of the multiple cytokine-release syndrome, all six patients survived. Documentation of the clinical course occurring over the 30 days after infusion offers insight into the systemic inflammatory response syndrome in the absence of contaminating pathogens, endotoxin, or underlying disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Although the solid phase assay does not replicate in vivo presentation of TGN1412, which is not fully understood, it does induce substantial cytokine release equivalent to that reported in trial volunteers.”
From Severity of the TGN 1412 trial disaster cytokine storm correlated with IL‐2 release (2013) · cites this paper as [2]
Experimental — accuracy not yet measuredIn the citing paper
“In 2006, a life-threatening 'cytokine storm', not predicted by pre-clinical safety testing, rapidly occurred in all six healthy volunteers during the phase I clinical trial of the CD28 superagonist monoclonal antibody (mAb) TGN1412.”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“One of the most striking features of the TGN1412-mediated 'cytokine storm' observed in humans was substantial TNF-a release within the first hour of infusion followed by dramatic increases in IFN-g, IL-2, IL-6, IL-8 and IL-10 plasma concentrations within 4 h (Suntharalingam et al., 2006).”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“Concentrations of TNF-a measured by ELISA in culture supernatants collected 24 h after in vitro TGN1412 stimulation were also consistent with the peak concentrations reported in trial volunteers, with the considerable caveat that a comparison is being made between an in vitro system and an in vivo response.”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“However, despite similar in vitro expression kinetics for IFN-g following TGN1412 stimulation, the concentrations of IFN-g were far lower than TNF-a responses in vitro, and an order of magnitude lower than concentrations of IFN-g predicted from in vivo responses in trial participants (Suntharalingam et al., 2006).”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
35 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“10.1073/pnas.0501997102”
Cited work 10.1073/pnas.0501997102 · retracted 2009-07-09 · notice 10.1073/pnas.0906977106 · this paper published 2006-09-07
Citations
Cites
1 retracted
Gon, Y., Wood, M. R., Kiosses, W. B., Jo, E., Sanna, M. G., Chun, J., & Rosen, H. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501997102 · Cited by 128
RetractedBone, R. C., Balk, R. A., Cerra, F. B., Dellinger, R. P., Fein, A. M., Knaus, W. A., Schein, R. M. H., & Sibbald, W. J. (1992) · Chest · doi:10.1378/chest.101.6.1644 · Cited by 13,198
Bernard, G. R., Artigas, A., Brigham, K. L., Carlet, J., Falke, K., Hudson, L., Lamy, M., Legall, J. R., Morris, A., & Spragg, R. (1994) · American journal of respiratory and critical care medicine · doi:10.1164/ajrccm.149.3.7509706 · Cited by 6,746
Sepsis-Induced Apoptosis Causes Progressive Profound Depletion of B and CD4+ T Lymphocytes in Humans
Hotchkiss, R. S., Tinsley, K. W., Swanson, P. E., Schmieg, R. E., Hui, J. J., Chang, K. C., Osborne, D. F., Freeman, B. D., Cobb, J. P., Buchman, T. G., et al. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.11.6952 · Cited by 934
Clinical risks for development of the acute respiratory distress syndrome.
Hudson, L. D., Milberg, J. A., Anardi, D., & Maunder, R. J. (1995) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.151.2.7842182 · Cited by 890
Brivet, F. G., Kleinknecht, D. J., Loirat, P., & Landais, P. J. M. (1996) · Critical Care Medicine · doi:10.1097/00003246-199602000-00003 · Cited by 879
Winkler, U., Jensen, M., Manzke, O., Schulz, H., Diehl, V., & Engert, A. (1999) · Blood · doi:10.1182/blood.v94.7.2217.419k02_2217_2224 · Cited by 657
Wing, M. G., Moreau, T., Greenwood, J., Smith, R. M., Hale, G., Isaacs, J., Waldmann, H., Lachmann, P. J., & Compston, A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119110 · Cited by 257
Beyersdorf, N., Gaupp, S., Balbach, K., Schmidt, J., Toyka, K. V., Lin, C.-H., Hanke, T., Hünig, T., Kerkau, T., & Gold, R. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051060 · Cited by 203
Cited by
Items 101–200 of 2,162
Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity
Lesterhuis, W. J., Bosco, A., Millward, M. J., Small, M., Nowak, A. K., & Lake, R. A. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.233 · Cited by 243
Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view
Boswell, C. A., & Brechbiel, M. W. (2007) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2007.04.001 · Cited by 241
“Within 90 min of a single Ab infusion, serious physiological complications (including severe pain, extreme swelling, headache, nausea, diarrhea, myalgias, vasodilation and hypotension) occurred in six healthy individuals in TeGenero's Phase I clinical trial with an unconjugated Ab (anti-CD28 mAb) in 2006 [85–87].”
BackgroundImmune Responses to AAV in Clinical Trials
Mingozzi, F., & High, K. (2007) · Current Gene Therapy · doi:10.2174/156652307782151425 · Cited by 238
“However, translation of these results into clinical studies revealed some of the limits of animal models in fully predicting outcomes in humans, a finding by no means unique to gene transfer therapeutics [ Suntharalingam et al., 2006 ].”
ResultTreating Human Autoimmunity: Current Practice and Future Prospects
Rosenblum, M. D., Gratz, I. K., Paw, J. S., & Abbas, A. K. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003504 · Cited by 237
Alijotas-Reig, J., Esteve-Valverde, E., Belizna, C., Selva-O'Callaghan, A., Pardos-Gea, J., Quintana, A., Mekinian, A., Anunciacion-Llunell, A., & Miró-Mur, F. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102569 · Cited by 235
VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy
Lines, J. L., Sempere, L. F., Broughton, T., Wang, L., & Noelle, R. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0072 · Cited by 236
“org Cancer Immunol Res; 2(6) June 2014 513”
InfluentialOPAL, S. (2007) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2007.03.006 · Cited by 231
Dostalek, M., Gardner, I., Gurbaxani, B. M., Rose, R. H., & Chetty, M. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-012-0027-4 · Cited by 230
“The use of pharmacodynamic interactions to improve the pharmacological effect of mAbs is growing [307, 308].”
BackgroundAn RNA toolbox for cancer immunotherapy
Pastor, F., Berraondo, P., Etxeberria, I., Frederick, J., Sahin, U., Gilboa, E., & Melero, I. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.132 · Cited by 229
Targeting co-stimulatory molecules in autoimmune disease
Edner, N. M., Carlesso, G., Rush, J. S., & Walker, L. S. K. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0081-9 · Cited by 228
Shoenfeld, Y. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102538 · Cited by 227
“These four conditions include macrophage activating syndrome (MAS) [4], catastrophic antiphospholipid syndrome (cAPS) [7], septic shock and an adverse reaction to the biological compound anti-CD-28 [8].”
Impact of host cell line choice on glycan profile
Goh, J. B., & Ng, S. K. (2018) · Critical Reviews in Biotechnology · doi:10.1080/07388551.2017.1416577 · Cited by 225
Ketamine and Peripheral Inflammation
De Kock, M., Loix, S., & Lavand'homme, P. (2013) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12104 · Cited by 224
“lar matrix will be expressed [17].”
Bour‐Jordan, H., & Bluestone, J. A. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00775.x · Cited by 223
“Furthermore, the mechanism of action of CD28 superagonistic mAbs and in particular its preferential effect on Tregs versus Teff was dramatically called into question by the catastrophic result of a phase I safety study where administration of the superagonist led to life-threatening systemic inflammatory response synd…”
BackgroundMitigating the toxic effects of anticancer immunotherapy
Gangadhar, T. C., & Vonderheide, R. H. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.245 · Cited by 222
The Evolving Role of CD8+CD28− Immunosenescent T Cells in Cancer Immunology
Huff, W. X., Kwon, J. H., Henriquez, M., Fetcko, K., & Dey, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112810 · Cited by 217
“Although, in a phase I trial of systemic administration of CD28 superagonist monoclonal antibodies (mAb) (TGN1412), uncontrolled CD28 signaling led to a potent induction of downstream immune activation independent of TCR-CD3 complex resulting in catastrophic systemic inflammatory syndromes in six volunteer subjects [6…”
BackgroundBiologic therapies in rheumatology: lessons learned, future directions
Strand, V., Kimberly, R., & Isaacs, J. D. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2196 · Cited by 216
“All six recipients of TGN1412 developed pulmonary infiltrates, renal failure and disseminated intravascular coagulation, in association with transient lymphopaenia and monocytopaenia”
BackgroundPotential of immunomodulatory host defense peptides as novel anti-infectives
Easton, D. M., Nijnik, A., Mayer, M. L., & Hancock, R. E. W. (2009) · Trends in Biotechnology · doi:10.1016/j.tibtech.2009.07.004 · Cited by 215
“Immunostimulatory treatments can result in inflammatory tissue damage, autoimmunity or potentially fatal cytokine storms [17, 18] .”
BackgroundCurrent Status and Future Directions
Ito, F., & Chang, A. E. (2013) · Cited by 223
Sato, K., Sato, N., Xu, B., Nakamura, Y., Nagaya, T., Choyke, P. L., Hasegawa, Y., & Kobayashi, H. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf6843 · Cited by 213
Abrams, M. T., Koser, M. L., Seitzer, J., Williams, S. C., DiPietro, M. A., Wang, W., Shaw, A. W., Mao, X., Jadhav, V., Davide, J. P., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2009.208 · Cited by 209
An evaluation framework for new approach methodologies (NAMs) for human health safety assessment
Parish, S. T., Aschner, M., Casey, W., Corvaro, M., Embry, M. R., Fitzpatrick, S., Kidd, D., Kleinstreuer, N. C., Lima, B. S., Settivari, R. S., et al. (2020) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2020.104592 · Cited by 211
Plasticity in programming of effector and memory CD8+ T‐cell formation
Arens, R., & Schoenberger, S. P. (2010) · Immunological Reviews · doi:10.1111/j.0105-2896.2010.00899.x · Cited by 207
Mould, D. R., & Green, B. (2010) · BioDrugs · doi:10.2165/11530560-000000000-00000 · Cited by 207
T-cell costimulation–biology, therapeutic potential, and challenges.
Sharpe, A. H., & Abbas, A. K. (2006) · New England Journal of Medicine · doi:10.1056/nejmp068087 · Cited by 206
Regulatory T Cells Protect from Local and Systemic Bone Destruction in Arthritis
Zaiss, M. M., Frey, B., Hess, A., Zwerina, J., Luther, J., Nimmerjahn, F., Engelke, K., Kollias, G., Hünig, T., Schett, G., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903841 · Cited by 205
“We are aware of the TGN1412 (Tegenero Immuno Therapeutics) study with CD28 SA in humans (43), in which a cytokine storm, rather than an antiinflammatory response, was observed.”
BackgroundKong, H. Y., & Byun, J. (2013) · Biomolecules and Therapeutics · doi:10.4062/biomolther.2013.085 · Cited by 202
“Similar research on aptamers for use as costimulatory agonistic molecules is being conducted (Suntharalingam et al., 2006; Römer et al., 2011).”
BackgroundNew immune cell engagers for cancer immunotherapy
Fenis, A., Demaria, O., Gauthier, L., Vivier, E., & Narni-Mancinelli, E. (2024) · Nature Reviews Immunology · doi:10.1038/s41577-023-00982-7 · Cited by 203
“Broad T cell activation has been observed with CD28 superag-onists, but these molecules were found to be highly toxic in early clinical trials 39 .”
Vaccine-elicited Human T Cells Recognizing Conserved Protein Regions Inhibit HIV-1
Borthwick, N., Ahmed, T., Ondondo, B., Hayes, P., Rose, A., Ebrahimsa, U., Hayton, E.-J., Black, A., Bridgeman, A., Rosario, M., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2013.248 · Cited by 199
“This is a very important step forward, moving from promising preclinical observations in animals to detailed studies in humans, given that immune responses in experimental animals do not always predict how humans will respond [32, 33, 34].”
The storm has cleared: lessons from the CD28 superagonist TGN1412 trial
Hünig, T. (2012) · Nature Reviews Immunology · doi:10.1038/nri3192 · Cited by 194
T cell costimulation blockade blunts pressure overload-induced heart failure
Kallikourdis, M., Martini, E., Carullo, P., Sardi, C., Roselli, G., Greco, C. M., Vignali, D., Riva, F., Ormbostad Berre, A. M., Stølen, T. O., et al. (2017) · Nature Communications · doi:10.1038/ncomms14680 · Cited by 199
Costimulatory pathways in transplantation: challenges and new developments
Li, X. C., Rothstein, D. M., & Sayegh, M. H. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00781.x · Cited by 197
“However, clinical trials using a superagonist anti-CD28 antibody as an immunosuppressive agent ended with disastrous consequences as several patients died of the side-effects of massive T-cell activation in vivo (154).”
BackgroundThe Pharmaceutical Industry and the Future of Drug Development
Taylor, D. (2015) · Pharmaceuticals in the Environment · doi:10.1039/9781782622345-00001 · Cited by 192
Pien, G. C., Basner-Tschakarjan, E., Hui, D. J., Mentlik, A. N., Finn, J. D., Hasbrouck, N. C., Zhou, S., Murphy, S. L., Maus, M. V., Mingozzi, F., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36891 · Cited by 192
“In a phase I clinical trial the superagonist anti-CD28 monoclonal antibody TGN1412 induced a massive cytokine storm in human recipients, resulting in multiorgan failure in 6 healthy volunteers at 1/500th the dose that appeared safe in mice and nonhuman primates (44).”
BackgroundSilencing or Stimulation? siRNA Delivery and the Immune System
Whitehead, K. A., Dahlman, J. E., Langer, R. S., & Anderson, D. G. (2011) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-061010-114133 · Cited by 191
Sanmamed, M. F., Pastor, F., Rodriguez, A., Perez-Gracia, J. L., Rodriguez-Ruiz, M. E., Jure-Kunkel, M., & Melero, I. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.014 · Cited by 190
Brischwein, K., Parr, L., Pflanz, S., Volkland, J., Lumsden, J., Klinger, M., Locher, M., Hammond, S. A., Kiener, P., Kufer, P., et al. (2007) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318156750c · Cited by 187
The role of B7 family molecules in hematologic malignancy
Greaves, P., & Gribben, J. G. (2013) · Blood · doi:10.1182/blood-2012-10-385591 · Cited by 187
Translating dosages from animal models to human clinical trials—revisiting body surface area scaling
Blanchard, O. L., & Smoliga, J. M. (2015) · The FASEB Journal · doi:10.1096/fj.14-269043 · Cited by 183
Regulatory T Cells as Immunotherapy
Singer, B. D., King, L. S., & D’Alessio, F. R. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00046 · Cited by 183
“Indeed, a phase I clinical trial of TGN1412 – a super-agonistic anti-CD28 antibody – caused massive cytokine storm and multi-organ dysfunction in six healthy adults who required intensive care following administration of the drug (91).”
BackgroundChallenges and approaches for the development of safer immunomodulatory biologics
Sathish, J. G., Sethu, S., Bielsky, M.-C., de Haan, L., French, N. S., Govindappa, K., Green, J., Griffiths, C. E. M., Holgate, S., Jones, D., et al. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3974 · Cited by 185
“Out of the 40 licensed immunomodulatory biologics, 18 have been associated with serious infections, including reactivation of bacterial infections (for example, mycobacterial, streptococcal, listerial or meningococcal infections), viral infections (for example, hepatitis B virus (HBV) or HCV), fungal infections (for e…”
BackgroundMethodInfluentialAdvances in antibody-based therapy in oncology
Zinn, S., Vazquez-Lombardi, R., Zimmermann, C., Sapra, P., Jermutus, L., & Christ, D. (2023) · Nature Cancer · doi:10.1038/s43018-023-00516-z · Cited by 184
Sequential transcriptional changes dictate safe and effective antigen-specific immunotherapy
Burton, B. R., Britton, G. J., Fang, H., Verhagen, J., Smithers, B., Sabatos-Peyton, C. A., Carney, L. J., Gough, J., Strobel, S., & Wraith, D. C. (2014) · Nature Communications · doi:10.1038/ncomms5741 · Cited by 181
Immunotherapy of autoimmunity and cancer: the penalty for success
Caspi, R. R. (2008) · Nature Reviews Immunology · doi:10.1038/nri2438 · Cited by 181
Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes
England, J. T., Abdulla, A., Biggs, C. M., Lee, A. Y. Y., Hay, K. A., Hoiland, R. L., Wellington, C. L., Sekhon, M., Jamal, S., Shojania, K., et al. (2021) · Blood Reviews · doi:10.1016/j.blre.2020.100707 · Cited by 177
“Examples of the latter include the phase I clinical trial of TGN1412, an anti-CD28 monoclonal antibody that caused severe cytokine storm in healthy volunteers, and the cytokine release syndrome (CRS) following chimeric antigen receptor (CAR)-T cell therapy [21,22].”
InfluentialAustin, P. J., Kim, C. F., Perera, C. J., & Moalem-Taylor, G. (2012) · Pain · doi:10.1016/j.pain.2012.06.005 · Cited by 180
“When CD28 superagonist TGN1412 was tested in humans, it induced life-threatening side effects due to multiple cytokine-release syndromes [61].”
BackgroundCD3 bispecific antibody–induced cytokine release is dispensable for cytotoxic T cell activity
Li, J., Piskol, R., Ybarra, R., Chen, Y.-J. J., Li, J., Slaga, D., Hristopoulos, M., Clark, R., Modrusan, Z., Totpal, K., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aax8861 · Cited by 180
Engels, N., König, L. M., Heemann, C., Lutz, J., Tsubata, T., Griep, S., Schrader, V., & Wienands, J. (2009) · Nature Immunology · doi:10.1038/ni.1764 · Cited by 177
“The disastrous cytokine storm observed during a phase I clinical trial with the monoclonal CD28-specific antibody TGN1412 (ref”
BackgroundZhu, E. F., Gai, S. A., Opel, C. F., Kwan, B. H., Surana, R., Mihm, M. C., Kauke, M. J., Moynihan, K. D., Angelini, A., Williams, R. T., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.004 · Cited by 177
“The set of elevated cytokines observed in our system broadly overlaps with those seen in clinical presentation of “cytokine storm” (Suntharalingam et al., 2006; Winkler et al., 1999), indicative of a broad and strong immune activation within the tumor.”
Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases
Hafeez, U., Gan, H. K., & Scott, A. M. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.05.010 · Cited by 176
White, A. L., Chan, H. T. C., French, R. R., Willoughby, J., Mockridge, C. I., Roghanian, A., Penfold, C. A., Booth, S. G., Dodhy, A., Polak, M. E., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.001 · Cited by 173
“…is both unexpected and unexplained, as almost all agonistic mAbs described to date, including the anti-CD28 superagonist TGN1412, which caused catastrophic toxicity in healthy volunteers in 2006 (Suntharalingam et al., 2006), require FcgR crosslinking for activity (Bartholomaeus et al., 2014).”
Too Much of a Good Thing? Tim-3 and TCR Signaling in T Cell Exhaustion
Ferris, R. L., Lu, B., & Kane, L. P. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400557 · Cited by 173
Immunosuppression for in vivo research: state-of-the-art protocols and experimental approaches
Diehl, R., Ferrara, F., Müller, C., Dreyer, A. Y., McLeod, D. D., Fricke, S., & Boltze, J. (2017) · Cellular & Molecular Immunology · doi:10.1038/cmi.2016.39 · Cited by 174
Stress: Definition and History
Fink, G. (2009) · Encyclopedia of Neuroscience · doi:10.1016/b978-008045046-9.00076-0 · Cited by 175
FcγR dependent mechanisms of cytotoxic, agonistic, and neutralizing antibody activities
Nimmerjahn, F., Gordan, S., & Lux, A. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.04.005 · Cited by 172
The anti-inflammatory effects of ketamine: state of the art.
Loix, S., Kock, M. D., & Henin, P. (2011) · PubMed · Cited by 174
Autoimmunity associated with immunotherapy of cancer
Amos, S. M., Duong, C. P. M., Westwood, J. A., Ritchie, D. S., Junghans, R. P., Darcy, P. K., & Kershaw, M. H. (2011) · Blood · doi:10.1182/blood-2011-01-325266 · Cited by 171
Abboud, R., Keller, J., Slade, M., DiPersio, J. F., Westervelt, P., Rettig, M. P., Meier, S., Fehniger, T. A., Abboud, C. N., Uy, G. L., et al. (2016) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2016.06.010 · Cited by 169
The Gut Microbiome in Hypertension: Recent Advances and Future Perspectives
Avery, E. G., Bartolomaeus, H., Maifeld, A., Marko, L., Wiig, H., Wilck, N., Rosshart, S. P., Forslund, S. K., & Müller, D. N. (2021) · Circulation Research · doi:10.1161/circresaha.121.318065 · Cited by 168
Advances in Cancer Immunotherapy in Solid Tumors
Menon, S., Shin, S., & Dy, G. (2016) · Cancers · doi:10.3390/cancers8120106 · Cited by 166
“Such initial demonstration of safety is critical, given known life-threatening complications of systemic inflammatory and immune reaction, as first encountered in the development of an anti-CD28 superagonist antibody TGN1412 [69].”
Functional cell models of the gut and their applications in food microbiology — A review
Cencič, A., & Langerholc, T. (2010) · International Journal of Food Microbiology · doi:10.1016/j.ijfoodmicro.2010.03.026 · Cited by 166
“Moreover, results obtained in such models were difficult to reproduce, were not clearly linked to clinical outcomes and were outside any physiology of host (Clancy, 2003; Suntharalingam et al., 2006).”
ResultGoldszmid, R. S., & Trinchieri, G. (2012) · Nature Immunology · doi:10.1038/ni.2422 · Cited by 166
CD28 Costimulation Is Essential for Human T Regulatory Expansion and Function
Golovina, T. N., Mikheeva, T., Suhoski, M. M., Aqui, N. A., Tai, V. C., Shan, X., Liu, R., Balcarcel, R. R., Fisher, N., Levine, B. L., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.4.2855 · Cited by 164
“This was unfortunately highlighted by the tragic outcome of the administration of superagonistic anti-CD28 Abs to healthy volunteers (50) that was not predicted by studies in rodents.”
BackgroundSong, X.-T., Kabler, K. E., Shen, L., Rollins, L., Huang, X. F., & Chen, S.-Y. (2008) · Nature Medicine · doi:10.1038/nm1721 · Cited by 163
“However, the nonspecific overactivation of self-reactive T cells, unsatisfactory clinical efficacy and pathological autoimmune toxicity that has been observed in clinical trials of these antibodie”
BackgroundMonoclonal antibody-induced cytokine-release syndrome
Bugelski, P. J., Achuthanandam, R., Capocasale, R. J., Treacy, G., & Bouman-Thio, E. (2009) · Expert Review of Clinical Immunology · doi:10.1586/eci.09.31 · Cited by 161
Therapeutic Potential of Mesenchymal Stem Cells for Severe Acute Lung Injury
Matthay, M. A., Thompson, B. T., Read, E. J., McKenna, D. H., Liu, K. D., Calfee, C. S., & Lee, J. W. (2010) · Chest · doi:10.1378/chest.10-0518 · Cited by 160
Aging predisposes to acute inflammatory induced pathology after tumor immunotherapy
Bouchlaka, M. N., Sckisel, G. D., Chen, M., Mirsoian, A., Zamora, A. E., Maverakis, E., Wilkins, D. E. C., Alderson, K. L., Hsiao, H.-H., Weiss, J. M., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20131219 · Cited by 160
Kell, D. B., & Pretorius, E. (2015) · Integrative Biology · doi:10.1039/c5ib00158g · Cited by 160
REVIEW ARTICLE: Regulatory T Cells and Their Role in Pregnancy
Leber, A., Teles, A., & Zenclussen, A. C. (2010) · American Journal of Reproductive Immunology · doi:10.1111/j.1600-0897.2010.00821.x · Cited by 162
Targeting co-stimulatory pathways: transplantation and autoimmunity
Ford, M. L., Adams, A. B., & Pearson, T. C. (2014) · Nature Reviews Nephrology · doi:10.1038/nrneph.2013.183 · Cited by 157
At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC
Otano, I., Ucero, A. C., Zugazagoitia, J., & Paz-Ares, L. G. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00718-x · Cited by 184
Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells
Xu, X.-J., & Tang, Y.-M. (2014) · Cancer Letters · doi:10.1016/j.canlet.2013.10.004 · Cited by 156
“The anti-IL-2 receptor antagonist antibody has been administrated with high-dose methylprednisolone to treat the CRS induced by TGN1412 [23].”
BackgroundDong, J. Q., Salinger, D. H., Endres, C. J., Gibbs, J. P., Hsu, C.-P., Stouch, B. J., Hurh, E., & Gibbs, M. A. (2011) · Clinical Pharmacokinetics · doi:10.2165/11537430-000000000-00000 · Cited by 156
“In addition, the TeGenero TGN1412 case([4]) led to increased regulatory hurdles with regard to safe starting dose selection for first-in-human (FIH) clinical trials.”
BackgroundTargeting Negative and Positive Immune Checkpoints with Monoclonal Antibodies in Therapy of Cancer
Marhelava, K., Pilch, Z., Bajor, M., Graczyk‐Jarzynka, A., & Zagożdżon, R. (2019) · Cancers · doi:10.3390/cancers11111756 · Cited by 170
“Unexpectedly, in all cases, theralizumab induced a severe cytokine release syndrome with a high proportion of multiple organ failure [87].”
BackgroundRömer, P. S., Berr, S., Avota, E., Na, S.-Y., Battaglia, M., ten Berge, I., Einsele, H., & Hünig, T. (2011) · Blood · doi:10.1182/blood-2010-12-319780 · Cited by 153
Fransen, M. F., Sluijter, M., Morreau, H., Arens, R., & Melief, C. J. M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2888 · Cited by 153
“[20] Suntharalingam G, Perry MR, Ward S, et al.”
BackgroundBourquin, C., Anz, D., Zwiorek, K., Lanz, A.-L., Fuchs, S. P., Weigel, S., Wurzenberger, C., von der Borch, P., Golić, M., Moder, S., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.5.2990 · Cited by 174
Vafa, O., Gilliland, G. L., Brezski, R. J., Strake, B., Wilkinson, T., Lacy, E. R., Scallon, B. J., Teplyakov, A., Malia, T., & Strohl, W. R. (2013) · Methods · doi:10.1016/j.ymeth.2013.06.035 · Cited by 172
Lesokhin, A. M., Callahan, M. K., Postow, M. A., & Wolchok, J. D. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.3010274 · Cited by 152
Treg(s) in Cancer: Friends or Foe?
Wolf, D., Sopper, S., Pircher, A., Gastl, G., & Wolf, A. M. (2015) · Journal of Cellular Physiology · doi:10.1002/jcp.25016 · Cited by 151
The Role of Fc Receptors on the Effectiveness of Therapeutic Monoclonal Antibodies
Gogesch, P., Dudek, S., van Zandbergen, G., Waibler, Z., & Anzaghe, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168947 · Cited by 172
“Amongst other immune activating processes, also crosslinking of the TGN1412 Fc part has been observed to be critically involved in inducing cytokine secretion in vitro [41,75].”
BackgroundCytokine and Chemokine Signals of T‐Cell Exclusion in Tumors
Zhang, Y., Guan, X.-Y., & Jiang, P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.594609 · Cited by 133
Butyrophilin 3A1 Plays an Essential Role in Prenyl Pyrophosphate Stimulation of Human Vγ2Vδ2 T Cells
Wang, H., Henry, O., Distefano, M. D., Wang, Y.-C., Räikkönen, J., Mönkkönen, J., Tanaka, Y., & Morita, C. T. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300658 · Cited by 148
Skokos, D., Waite, J. C., Haber, L., Crawford, A., Hermann, A., Ullman, E., Slim, R. M., Godin, S., Ajithdoss, D. K., Ye, X., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw7888 · Cited by 160
Muller, P. Y., Milton, M., Lloyd, P. M., Sims, J., & Brennan, F. R. (2009) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2009.10.013 · Cited by 152
Bojadzic, D., Alcazar, O., Chen, J., Chuang, S.-T., Capcha, J. M. C., Shehadeh, L. A., & Buchwald, P. (2021) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.1c00070 · Cited by 155
Ebeling, M., Küng, E., See, A., Broger, C., Steiner, G., Berrera, M., Heckel, T., Iniguez, L., Albert, T., Schmucki, R., et al. (2011) · Genome Research · doi:10.1101/gr.123117.111 · Cited by 145
Immunogenicity to Biologics: Mechanisms, Prediction and Reduction
Sethu, S., Govindappa, K., Alhaidari, M., Pirmohamed, M., Park, K., & Sathish, J. G. (2012) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-012-0189-7 · Cited by 168
“…biologic-induced or biologic-associated infectious complications (Bongartz et al. 2006; Rychly and DiPiro 2005), unwanted immunostimulation (Suntharalingam et al. 2006), anti-drug antibody (ADA) generation (Aarskog et al. 2009; Li et al. 2001; Sorensen et al. 2003) and hypersensitivity…”
Compte, M., Harwood, S. L., Muñoz, I. G., Navarro, R., Zonca, M., Perez-Chacon, G., Erce-Llamazares, A., Merino, N., Tapia-Galisteo, A., Cuesta, A. M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07195-w · Cited by 142
Small Molecules Drive Big Improvements in Immuno‐Oncology Therapies
Huck, B. R., Kötzner, L., & Urbahns, K. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201707816 · Cited by 144
T-cell activation profiles distinguish hemophagocytic lymphohistiocytosis and early sepsis
Chaturvedi, V., Marsh, R. A., Zoref‐Lorenz, A., Owsley, E., Chaturvedi, V., Nguyen, T. C., Goldman, J. R., Henry, M. M., Greenberg, J. N., Ladisch, S., et al. (2020) · Blood · doi:10.1182/blood.2020009499 · Cited by 158
Therapeutic antibodies, vaccines and antibodyomes
Dimitrov, D. S. (2010) · mAbs · doi:10.4161/mabs.2.3.11779 · Cited by 149
“In a notable case, induction of a systemic inflammatory response characterized by a rapid induction of pro-inflammatory cytokines within 90 minutes of administration of a single dose of the stimulatory anti-CD28 mAb TGN1412 occurred in all six volunteers, leading to critical illness in 12 to 16 hours.(21) In another e…”
BackgroundThe ABC of clinical and experimental adjuvants—A brief overview
Brunner, R., Jensen‐Jarolim, E., & Pali‐Schöll, I. (2009) · Immunology Letters · doi:10.1016/j.imlet.2009.10.005 · Cited by 169
“Shortly after application all patients needed intensive care due to cardiovascular shock and acute respiratory distress syndrome caused by cytokine storm [25].”
BackgroundHernandez-Chacon, J. A., Li, Y., Wu, R. C. H., Bernatchez, C., Wang, Y., Weber, J. S., Hwu, P., & Radvanyi, L. G. (2011) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318209e7ec · Cited by 141
“Using a novel superagonist anti-CD28 mAb in clinical trials also resulted in a disastrous cytokine storm.(36) The patients exhibited headache, nausea, vomiting, and other severe side effects within 90 minutes of receiving a single intravenous injection of the superagonist anti-CD28 mAb.”
BackgroundCancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists
Peggs, K. S., Quezada, S. A., & Allison, J. P. (2009) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2009.03912.x · Cited by 141
Tarrant, J. M. (2010) · Toxicological Sciences · doi:10.1093/toxsci/kfq134 · Cited by 141
“Cynomologous macaques did not predict the exaggerated immune stimulation (cytokine storm) experienced in the phase I clinical trial (Suntharalingam et al., 2006).”
BackgroundImmune Checkpoints as Therapeutic Targets in Autoimmunity
Paluch, C., Santos, A. M., Anzilotti, C., Cornall, R. J., & Davis, S. J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02306 · Cited by 140
Riegler, L. L., Jones, G. P., & Lee, D. W. (2019) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s150524 · Cited by 158
CD28 co-stimulation in T-cell homeostasis: a recent perspective
Hünig, T., Beyersdorf, N., & Kerkau, T. (2015) · ImmunoTargets and Therapy · doi:10.2147/itt.s61647 · Cited by 194
“97 However, when the human CD28SA TGN1412 was tested in a first-in-human (FIH) trial in 2006, the healthy volunteers experienced a life-threatening cytokine storm, 98 which resulted from the activation of tissue-resident CD4 + effector memory cells.”
Metadata
- Authors
- Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N.
- Affiliations
- Hammersmith Hospital (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-09-07
- Volume
- 355
- Issue
- 10
- Pages
- 1018-1028
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2141989396
- Cited by
- 2,164
- References
- 18
- Citations by year
- 2026: 57 · 2025: 73 · 2024: 95 · 2023: 79 · 2022: 79 · 2021: 120 · 2020: 141 · 2019: 94 · 2018: 102 · 2017: 97 · 2016: 117 · 2015: 122 · 2014: 118 · 2013: 120 · 2012: 114
- FWCI
- 80.54
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Keywords
- cytokine release syndrome, TGN1412, anti-CD28 monoclonal antibody, systemic inflammatory response syndrome, inflammatory cytokines, acute respiratory distress syndrome, disseminated intravascular coagulation, renal failure, drug-induced immunotoxicity
- MeSH terms
- Adult, Antibodies, Monoclonal, C-Reactive Protein, Critical Care, Double-Blind Method, Hemodynamics, Humans, Hypotension, Infusions, Intravenous, Leukopenia, Male, Multiple Organ Failure, Thrombocytopenia, Cytokines, CD28 Antigens, Disease Progression, APACHE, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.